Lipid Disorder Treatment Market Growth Accelerates: Strategic Forecast Predicts $19.56 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Lipid Disorder Treatment Industry Market Size Be by 2025?
The market size for treatment of lipid disorders has seen a swift expansion over the recent years. The market, which is worth $10.69 billion in 2024, is set to increase to $12.09 billion the following year, marking a compound annual growth rate (CAGR) of 13.2%. Factors contributing to this growth in the previous period include a heightened uptake of a sedentary lifestyle, a surge in the working populace, improved knowledge about the disease and its treatments, an increase in desk job prevalence, and a rise in occurrences of familial combined hyperlipidemia.

What's the Long-Term Growth Forecast for the Lipid Disorder Treatment Market Size Through 2029?
A surge in growth is projected for the lipid disorder treatment market in the upcoming years, with its worth expected to reach $19.56 billion by the year 2029, reflecting a compound annual growth rate (CAGR) of 12.8%. This forecasted expansion is linked to rising obesity and high cholesterol levels, increasing instances of cardiovascular diseases, increasing incidence of heart diseases due to high cholesterol, growing demand for safe and effective treatments, and overindulgence in alcohol and smoking. Significant trends anticipated during the forecast period encompass technological breakthroughs in pharmaceutical development, product inventiveness, expanded investment in business growth, advanced technology in treatment facilities, and clinical progress.

View the full report here:
https://www.thebusinessresearchcompany.com/report/lipid-disorder-treatment-global-market-report

What Are the Key Growth Drivers Fueling the Lipid Disorder Treatment Market Expansion?
The lipid disorder treatment market is expected to expand due to the increasing incidents of obesity and high cholesterol. Obesity is described as the over-accumulation of body fat, whereas high cholesterol is defined by elevated cholesterol levels in the bloodstream, both of which present serious health hazards. Factors such as unhealthy eating habits, lack of physical activity, genetic factors, and environmental impacts contribute to the rise of obesity and high cholesterol. Lipid disorder treatment is critical in managing these conditions, utilizing a blend of medicinal interventions, lifestyle changes, weight control initiatives, patient awareness, and holistic medical care. For example, data from the World Obesity Atlas 2022, released by the UK-based World Obesity Federation in May 2022, predicts that one billion people across the globe, including one-fifth of women and one-seventh of men, will suffer from obesity by 2030. This number will rise to four billion people, representing 51% of the world's population, by 2035. Hence, the consistently increasing instances of obesity and high cholesterol are fueling the lipid disorder treatment market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15600&type=smp

What Are the Key Trends Driving Lipid Disorder Treatment Market Growth?
In the lipid disorder treatment market, key companies are focusing on developing PCSK9 inhibitors to tackle the demand for more specialized and efficient treatments for elevated cholesterol levels. PCSK9 inhibitors address lipid disorders by increasing the removal of LDL cholesterol from the bloodstream, which in turn lowers the risk of cardiovascular incidents among high-risk patients. For example, US-based biotech firm Regeneron Pharmaceuticals Inc. secured approval in March 2024 from the U.S. FDA for the Praluent (alirocumab) injection to treat heterozygous familial hypercholesterolemia (HeFH) in children 8 years and older. The distinct advantage of the Praluent injection is its ability to prevent the PCSK9 from binding to the LDL receptor, improving the number of LDL receptors on liver cell surfaces. This aids in the clearance of LDL and helps decrease LDL-C levels in the bloodstream.

How Is the Lipid Disorder Treatment Market Segmented?
The lipid disorder treatment market covered in this report is segmented -

1) By Drug Type: Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, Other Drugs
2) By Indication: Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein B-100, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:
1) By Atorvastatin: Generic Atorvastatin, Brand-Name Atorvastatin ( Lipitor)
2) By Fluvastatin: Generic Fluvastatin, Brand-Name Fluvastatin ( Lescol)
3) By Rosuvastatin: Generic Rosuvastatin, Brand-Name Rosuvastatin ( Crestor)
4) By Simvastatin: Generic Simvastatin, Brand-Name Simvastatin ( Zocor)
5) By Pravastatin: Generic Pravastatin, Brand-Name Pravastatin ( Pravachol)
6) By Other Drugs: Ezetimibe, Pcsk9 Inhibitors ( Alirocumab, Evolocumab), Fibrates ( Gemfibrozil, Fenofibrate), Niacin (Vitamin B3), Omega-3 Fatty Acids ( Icosapent Ethyl)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15600&type=smp

Which Companies Are Leading the Charge in Lipid Disorder Treatment Market Innovation?
Major companies operating in the lipid disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Fresenius SE & Co. KGaA, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline Plc, Wockhardt Ltd., Eli Lilly and Company, Amgen Inc., Boehringer-Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Kaneka Corporation, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Kowa Pharmaceuticals America Inc., Concord Biotech Limited, Biocon Ltd., Ranbaxy Laboratories Limited

Which Regions Are Leading the Global Lipid Disorder Treatment Market in Revenue?
North America was the largest region in the lipid disorder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15600

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.